Clinical Trials Logo

Clinical Trial Summary

The pathogenesis of cancer anorexia is complex and multifactorial. However, a number of consistent and robust evidence point to a prominent role for the central nervous system. In particular, the hyperactivation of the immune system, due to tumour growth, causes a systemic inflammatory response primarily mediated by pro-inflammatory cytokines. At the central level, inflammatory response profoundly alters the activity of the hypothalamic nuclei, which are involved in the regulation of energy homeostasis. In particular, pro-inflammatory cytokines inhibit prophagic neurons activity, while enhance the activation of the anorexigenic neurons. Although supported by compelling experimental evidence, it should be acknowledged that this pathogenic hypothesis has not been confirmed yet by human studies.

Aim of the present study is to determine the specific pattern(s) of the brain activation after assumption of a standard meal in both anorexic and non-anorexic cancer patients to reveal potential differences, which will be correlated with the levels of concurrently measured circulating pro-inflammatory cytokines. The results obtained would help in assessing the role of the central nervous system and, in particular of the hypothalamus, in the pathogenesis of cancer anorexia.


Clinical Trial Description

After approval of the study protocol by the Ethical Committee of our Institution (Azienda Policlinico Umberto I, Sapienza University, Rome, Italy), 9 anorexic cancer patients, 4 non-anorexic cancer patients and 2 healthy individuals will be studied. The sample size is based on studies of neuroimaging already published and available on international journals.

Patients with confirmed cancer diagnosis will be enrolled before the initiation of any anti-cancer treatments. The presence/absence of anorexia will be investigated using a specific questionnaire (Cangiano et al., 1990) and a visual analogue scale (VAS). After an overnight fasting, blood samples will be collected from cancer patients and control subjects and interleukin(IL)-1, IL-6 and Tumor Necrosis Factor-α (TNF-α) levels will be measured by a commercially available ELISA kit.

On the same day, hypothalamic activation pattern(s) will be evaluated in patients and in control subjects by fMRI. After basal evaluation, all the groups will receive a standard oral meal, i.e., a 200 mL hypercaloric oral nutritional supplement providing 300 Kcal, and then a second fMRI scan will be performed. Using a computerized software, the average value of the grey for the hypothalamus will be calculated, and normalized for the one obtained in the basal condition, to obtain the percentage (%) of activation (or inhibition) of the hypothalamus.

Data obtained will be statistically analyzed using the t-Student and Bonferroni tests. ;


Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT01564693
Study type Observational
Source University of Roma La Sapienza
Contact
Status Completed
Phase N/A
Start date April 2010
Completion date April 2015

See also
  Status Clinical Trial Phase
Recruiting NCT02553187 - A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Phase 4
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT01206335 - Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia Phase 2
Completed NCT00378131 - Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia Phase 2
Completed NCT02359123 - Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients N/A
Completed NCT00267358 - Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia. Phase 2
Completed NCT03144128 - Vitamin D for Muscle Metabolic Function in Cancer Cachexia N/A
Completed NCT01614990 - Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia Phase 2
Recruiting NCT04065815 - Protein-rich Nutritional Therapy Combined With Time-efficient Exercise in Cancer Therapy N/A
Recruiting NCT04067167 - Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases N/A
Active, not recruiting NCT03851133 - Florida Pancreas Collaborative Next Generation Biobank
Completed NCT05264038 - A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514 Phase 1
Recruiting NCT04127981 - Medical Imaging of Cachexia N/A
Not yet recruiting NCT05262192 - Nutrition Education and Quality of Life in Cancer Cachexia N/A
Completed NCT04153019 - PSYCHO-EDUCATIONAL AND REHABILITATIVE INTERVENTION FOR CANCER CACHEXIA (PRICC) N/A
Terminated NCT02066363 - Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer N/A
Terminated NCT01505764 - The Role of Ghrelin in Cancer Cachexia Phase 2
Completed NCT00219817 - Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss Phase 2
Completed NCT00094562 - A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss Phase 2
Recruiting NCT04131478 - Effect of Gene Polymorphisms on the Pathogenesis of Cancer Cachexia